Skip to main content
. 2024 Jan 18;10(2):e24796. doi: 10.1016/j.heliyon.2024.e24796

Table 3.

Clinical response of immune checkpoint inhibitors.

ORR DCR Median PFS (months)
First line (n = 7) 5 (71.4%) 7 (100%) 7.5
Subsequent line (n = 9) 1 (11%) 6 (66.7%) 4.7
PD-L1 positive (n = 8) 3 (37.5%) 6 (75%) 6.6
PD-L1 negative or unknown (n = 8) 3 (37.5%) 7 (87.5%) 6.1
PD-L1 high (≥50%)
(n = 4)
3 (75%) 4 (100%) 5.6

Abbreviations: ORR: objective response rate. DCR: disease control rate. PFS: progression-free survival.